Impact of patient-specific factors on clozapine metabolism in individuals with treatment-resistant schizophrenia or schizoaffective disorder.

IF 4.5 3区 医学 Q1 CLINICAL NEUROLOGY Journal of Psychopharmacology Pub Date : 2024-06-01 Epub Date: 2024-03-23 DOI:10.1177/02698811241241394
Reza Rafizadeh, Anmol Sooch, Alessia Risi, Nicoline Bihelek, Kyler Kanegawa, Alasdair M Barr, Randall F White, Christian G Schütz, Chad A Bousman
{"title":"Impact of patient-specific factors on clozapine metabolism in individuals with treatment-resistant schizophrenia or schizoaffective disorder.","authors":"Reza Rafizadeh, Anmol Sooch, Alessia Risi, Nicoline Bihelek, Kyler Kanegawa, Alasdair M Barr, Randall F White, Christian G Schütz, Chad A Bousman","doi":"10.1177/02698811241241394","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There is high inter-individual variability in clozapine metabolism due to genetic and non-genetic differences. Patient-specific factors such as smoking, inflammation indicated by elevated C-reactive protein (CRP), and certain concurrent medications have a significant influence on clozapine metabolism.</p><p><strong>Aim: </strong>To assess which patient-specific factors best explain variability in clozapine metabolism estimated by clozapine concentration to dose (C/D) ratios.</p><p><strong>Methods: </strong>A retrospective cohort analysis using electronic medical data was conducted on 172 inpatients at the BC Psychosis Program. Patients with normal renal and liver function were included if they were on clozapine and had at least one steady-state plasma concentration. The degree of influence of each factor on the variability of clozapine metabolism in the entire cohort and subgroups stratified by fluvoxamine use was evaluated using multiple linear regression analysis of C/D ratios.</p><p><strong>Results: </strong>Model fit testing showed that the entire cohort model accounts for 52.7% of C/D ratio variability, while the no fluvoxamine and fluvoxamine models accounted for 40.8% and 43.8%. In the entire cohort (<i>n</i> = 172), fluvoxamine use explained the highest variance, and C/D ratios were higher by 30.6% on average. The second strongest predictor was elevated CRP > 10 mg/L, and C/D ratios were higher by 22.9% on average. Subsequently, obesity, nonsmoker status, and female sex explained a significant but modest proportion of variance. Among participants on fluvoxamine (<i>n</i> = 58), only fluvoxamine dose was associated with an increase, and for every 25 mg increase in dose, C/D ratios increased by 5% on average.</p><p><strong>Conclusion: </strong>In a clinical population, this study replicated the relationship between reduced rate of clozapine metabolism and the use of fluvoxamine, elevated CRP, obesity, nonsmoking status, and female sex; and the magnitude of the effects were large enough to be clinically relevant.</p>","PeriodicalId":16892,"journal":{"name":"Journal of Psychopharmacology","volume":" ","pages":"526-531"},"PeriodicalIF":4.5000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179308/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02698811241241394","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: There is high inter-individual variability in clozapine metabolism due to genetic and non-genetic differences. Patient-specific factors such as smoking, inflammation indicated by elevated C-reactive protein (CRP), and certain concurrent medications have a significant influence on clozapine metabolism.

Aim: To assess which patient-specific factors best explain variability in clozapine metabolism estimated by clozapine concentration to dose (C/D) ratios.

Methods: A retrospective cohort analysis using electronic medical data was conducted on 172 inpatients at the BC Psychosis Program. Patients with normal renal and liver function were included if they were on clozapine and had at least one steady-state plasma concentration. The degree of influence of each factor on the variability of clozapine metabolism in the entire cohort and subgroups stratified by fluvoxamine use was evaluated using multiple linear regression analysis of C/D ratios.

Results: Model fit testing showed that the entire cohort model accounts for 52.7% of C/D ratio variability, while the no fluvoxamine and fluvoxamine models accounted for 40.8% and 43.8%. In the entire cohort (n = 172), fluvoxamine use explained the highest variance, and C/D ratios were higher by 30.6% on average. The second strongest predictor was elevated CRP > 10 mg/L, and C/D ratios were higher by 22.9% on average. Subsequently, obesity, nonsmoker status, and female sex explained a significant but modest proportion of variance. Among participants on fluvoxamine (n = 58), only fluvoxamine dose was associated with an increase, and for every 25 mg increase in dose, C/D ratios increased by 5% on average.

Conclusion: In a clinical population, this study replicated the relationship between reduced rate of clozapine metabolism and the use of fluvoxamine, elevated CRP, obesity, nonsmoking status, and female sex; and the magnitude of the effects were large enough to be clinically relevant.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
耐药精神分裂症或分裂情感障碍患者的特定因素对氯氮平代谢的影响。
背景:由于基因和非基因差异,氯氮平的代谢存在很大的个体差异。患者的特异性因素,如吸烟、C反应蛋白(CRP)升高所显示的炎症以及某些同时服用的药物对氯氮平代谢有显著影响:利用电子医疗数据对不列颠哥伦比亚省精神病项目的 172 名住院患者进行了回顾性队列分析。肾功能和肝功能正常的患者只要服用氯氮平并至少有一次稳态血浆浓度,就被纳入研究范围。通过对C/D比值进行多元线性回归分析,评估了各因素对整个组群和按氟伏沙明使用情况分层的亚组中氯氮平代谢变异性的影响程度:模型拟合度测试表明,整个队列模型占C/D比率变异的52.7%,而无氟伏沙明和氟伏沙明模型分别占40.8%和43.8%。在整个队列(n = 172)中,使用氟伏沙明解释的变异最大,C/D 比值平均高出 30.6%。第二大预测因素是 CRP 升高 > 10 mg/L,C/D 比值平均升高 22.9%。随后,肥胖、不吸烟状态和女性性别也解释了相当大但比例不大的变异。在服用氟伏沙明(n = 58)的参与者中,只有氟伏沙明的剂量与C/D比值升高有关,剂量每增加25毫克,C/D比值平均升高5%:结论:在临床人群中,本研究重复了氯氮平代谢率降低与使用氟伏沙明、CRP升高、肥胖、不吸烟状态和女性性别之间的关系;其影响程度之大足以与临床相关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Psychopharmacology
Journal of Psychopharmacology 医学-精神病学
CiteScore
8.60
自引率
4.90%
发文量
126
审稿时长
3-8 weeks
期刊介绍: The Journal of Psychopharmacology is a fully peer-reviewed, international journal that publishes original research and review articles on preclinical and clinical aspects of psychopharmacology. The journal provides an essential forum for researchers and practicing clinicians on the effects of drugs on animal and human behavior, and the mechanisms underlying these effects. The Journal of Psychopharmacology is truly international in scope and readership.
期刊最新文献
High-dose Vitamin-B6 reduces sensory over-responsivity. Clinical effects of CYP2D6 phenoconversion in patients with psychosis. Influence of panic disorder and paroxetine on brain functional hubs in drug-free patients. Aspirin may be more suitable for patients with major depression: Evidence from two-sample Mendelian randomization analysis. Optimizing the individual dosing of paroxetine in major depressive disorder with therapeutic drug monitoring.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1